The α3β4 nicotinic acetylcholine
receptor (nAChR) is
an important target implicated in various disease states. α-Conotoxin
TxID (1) is the most potent antagonist of α3β4
nAChR, but it also exhibits inhibition of α6/α3β4
nAChR. The results of alanine scanning of 1 suggested
a vital role for Ser9 in the selectivity of the peptide. In this study,
Ser9 was substituted with a series of 14 amino acids, including some
non-natural amino acids, displaying different physicochemical characteristics
to further improve the selectivity of 1 toward α3β4
nAChR. The pharmacological activities of the mutants were evaluated
using an electrophysiological approach. The best selectivity was obtained
with [S9K]TxID, 12, which inhibited α3β4
nAChR with an IC50 of 6.9 nM and had no effects on other
nAChRs. Molecular modeling suggested a possible explanation for the
high selectivity of 12 toward α3β4 nAChR,
providing deeper insight into the interaction between α-conotoxins
and nAChRs as well as potential treatments for nAChR-related diseases